# Iparomlimab and Tuvonralimab in HNSCC

> **NCT07090317** · PHASE2 · RECRUITING · sponsor: **Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University** · enrollment: 30 (estimated)

## Conditions studied

- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab

## Key facts

- **NCT ID:** NCT07090317
- **Lead sponsor:** Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-31
- **Primary completion:** 2027-08-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07090317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07090317, "Iparomlimab and Tuvonralimab in HNSCC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07090317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*